Quick Answer
Cue Biopharma, Inc. reported R&D Expense of $37.74 million for fiscal year 2025.
Cue Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.74M | +4.0% |
| 2024 | $36.30M | -11.0% |
| 2023 | $40.80M | +5.8% |
| 2022 | $38.58M | -6.7% |
| 2021 | $41.35M | +23.3% |
| 2020 | $33.55M | +22.0% |
| 2019 | $27.49M | -3.7% |
| 2018 | $28.54M | +51.0% |
| 2017 | $18.90M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.75M | -49.3% | -39.9% |
| June 30, 2025 | $7.91M | -17.0% | -7.5% |
| March 31, 2025 | $8.55M | -16.2% | -8.9% |
| September 30, 2024 | $9.38M | -5.0% | -1.6% |
| June 30, 2024 | $9.53M | -10.5% | -6.6% |
| March 31, 2024 | $10.20M | +8.6% | +3.3% |
| September 30, 2023 | $9.87M | +30.4% | -7.3% |
| June 30, 2023 | $10.65M | +11.0% | +13.4% |
- Cue Biopharma, Inc. showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Cue Biopharma, Inc.’s r&d expense has grown by 99.7% (from $18.90 million to $37.74 million).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: